Association for Diagnostics & Laboratory Medicine // Advocacy & Outreach // Comment Letters // 2015 Comment Letters

2015 Comment Letters

In July 2023, we changed our name from AACC (short for the American Association for Clinical Chemistry) to the Association for Diagnostics & Laboratory Medicine (ADLM). The following page links to resources that were written prior to the rebranding and/or mentions events that took place prior to the rebranding and that contain mentions of the association’s old name.

AACC continually tracks legislative and regulatory issues of importance to clinical laboratories and the clinical laboratory profession. This is a listing of AACC's 2015 comment letters. AACC commented on a wide range of topics to federal and state authorities.

2015 Comment Letters

2015 Legislative and Regulatory Issues

AACC Proposes Broadening PAMA Reporting Requirements

AACC Raises Concerns About Expanded FDA Oversight of LDTs

AACC joined with the Friends of AHRQ in opposing cuts in AHRQ spending

AACC endorsed legislation to assist young researchers obtain NIH grants

AACC joined with other groups in supporting funding for an alternative National Children’s Study

AACC provided input to NIH on its new Environmental Influences on Child Health Outcomes Program

AACC joined the Friends of AHRQ in opposing cuts in agency funding

AACC wrote to House leaders opposing efforts to eliminate the Agency for Healthcare Research and Quality

AACC endorsed H.R.1190, the Protecting Seniors' Access to Medicare Act of 2015

AACC endorsed the Next Generation Researchers Act

AACC recommended CMS Establish a Transition Period for Expanded Blood Glucose Monitor Oversight

AACC joins the Friends of AHRQ in supporting federal funding for AHRQ

AACC wrote to key House and Senate leaders endorsing the President's Personalized Medicine Initiative

AACC urged FDA to maintain current oversight structure for next generation sequencing testing

AACC urged the FDA to maintain the existing regulatory structure for LDTs

AACC provided input regarding the FDA’s notification and medical device reporting proposals for LDTs

AACC and others urged NIH to spend National Children’s Study funds on pediatric research

AACC endorsed H.R.160, the Protect Medical Innovation Act

AACC endorsed S.141, the Protecting Seniors’ Access to Medicare Act

AACC provided testimony at the FDA Workshop on the regulation of LDTs

AACC provided input to the House Energy and Commerce Committee regarding LDTS